drugset
drugset / Trial / NCT06237777

A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients

NCT06237777 ↗

Phase 1 Unknown 18 enrolled Wang Min Lanyue Biotech (Hangzhou) Co., Ltd. · collab
NaSequentialOpen-labelTreatment

Summary

This is a clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106 intravitreal injection in diabetic macular edema (DME) patients.

Timeline

Start
2024-05
Primary completion
2026-01
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SKG0106 Gene therapy (AAV / viral vector) — Intravitreal

Indications

diabetic macular edema